Sulfated CCR5 peptides for HIV-1 infection

   
   

This invention provides a compound comprising the structure: YDINYYTSE wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein represents an amino group or an acetylated amino group; wherein represents a carboxyl group or an amidated carboxyl group; wherein all of ,Y,D,I,N,Y,Y,T,S,E and are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.

 
Web www.patentalert.com

< Polynucleotide quantitation method

< Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

> Method of preparing a eukaryotic viral vector

> Substituted phenylalkanoic acid derivatives and use thereof

~ 00189